Open Orphan PLC Investor Presentations
March 02 2022 - 2:01AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
02 March 2022
2 March 2022
Open Orphan plc
("Open Orphan" or the "Company")
Investor Presentations
Presentations to provide introduction to new CEO Yamin 'Mo'
Khan
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in testing
infectious and respiratory disease products using human challenge
clinical trials, announces it will provide two live investor
presentations in March 2022. The presentations will provide
investors with an introduction to new Chief Executive Officer,
Yamin 'Mo' Khan, who will make his maiden presentations on Company
progress.
London South East
Executive Chairman, Cathal Friel, and Chief Executive Officer,
Yamin 'Mo' Khan, will give a live investor presentation via London
South East alongside other companies as part of an investor webinar
on Tuesday 8 March at 7.30 pm (GMT). The presentation is free to
attend and requires investors to register via the London South East
website. This can be accessed with the following link:
https://us02web.zoom.us/webinar/register/3816460478728/WN_kyeX1ibCT0aXEUdkO9gIOg
Investor Meet Company
Executive Chairman, Cathal Friel, and Chief Executive Officer,
Yamin 'Mo' Khan, will host a second investor presentation via
Investor Meet Company ("IMC") on Tuesday 15 March at 6.00 pm (GMT).
Investors can sign up to Investor Meet Company for free and request
to meet Open Orphan plc via the following link:
https://www.investormeetcompany.com/open-orphan-plc/register-investor
Investors who already follow Open Orphan plc on the Investor
Meet Company platform will automatically be invited.
Questions can be submitted pre-event via your IMC dashboard or
in real time during the presentation. Whilst the Company may not be
in a position to answer every question it receives, it will address
the most prominent within the confines of regulations and
information already disclosed to the market through regulatory
notifications. A recording of the presentation will be available on
the Investor Meet Company platform afterwards. No new price
sensitive information will be disclosed, and a PDF of the
presentation will be uploaded to the Company's website.
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Yamin Khan, Chief Executive Officer
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Louisa Waddell
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson / Richard
Chambers
Davy (Euronext Growth Adviser and
Joint Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Paul McManus / Sam Allen / Louis +44 (0)7980 541 893 / +44 (0) 7502 558
Ashe-Jepson 258 / +44 (0)
7747 515393
Notes to Editors
Open Orphan plc
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
contract research company that is a world leader in testing
vaccines and antivirals using human challenge clinical trials. The
Company provides services to Big Pharma, biotech, and
government/public health organisations.
Open Orphan runs challenge studies in London from both its
19-bedroom Whitechapel quarantine clinic and its state-of-the-art
24-bedroom QMB clinic with its highly specialised on-site virology
and immunology laboratory. The Company has a leading portfolio of
human challenge study models for infectious and respiratory
diseases and is developing a number of new models. There has been
significant growth of the infectious disease market, which is
estimated to grow to in excess of $250bn by 2025. The Group is
focused on refreshing its existing challenge models and develop new
models, such as Malaria, to address the dramatic growth potential
of the global infectious disease market.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological, and digital (wearable) biomarkers. The
Disease in Motion platform has many potential applications across a
wide variety of end users including big technology, wearables,
pharma, and biotech companies.
Open Orphan's Paris office has been providing biometry, data
management and statistics to its many European pharmaceutical
clients for over 20 years. For over 15 years, the Company's
Netherlands office has been providing drug development consultancy
and services, including CMC (chemistry, manufacturing, and
controls), PK and medical writing, to a broad range of European
clients. Both offices are now also fully integrated with the London
office and working on challenge study contracts as well as
supporting third party trial contracts.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGZGGFNMKGZZM
(END) Dow Jones Newswires
March 02, 2022 02:01 ET (07:01 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024